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Abstract
Purpose The aims were to determine if the maximum
standardized uptake value (SUVmax) of the primary tumor
as determined by preoperative
18F-fluoro-2-deoxyglucose
(
18F-FDG) positron emission tomography (PET) is an
independent predictor of overall survival and to assess its
prognostic value after stratification according to pathological
staging.
Methods A retrospective clinicopathologic review of 363
patients who had a preoperative
18F-FDG PET done before
undergoing attempted curative resection for early-stage (I &
II) non-small cell lung cancer (NSCLC) was performed.
Patients who had received any adjuvant or neoadjuvant
chemotherapy or radiation therapy were excluded. The
primary outcome measure was duration of overall survival.
Receiver-operating characteristic (ROC) curves were plot-
ted to find out the optimal cutoff values of SUVmax yielding
the maximal sensitivity plus specificity for predicting the
overall survival. Survival curves stratified by median
SUVmax and optimal cutoff SUVmax were estimated by
the Kaplan-Meier method and statistical differences were
assessed using the log-rank test. Multivariate proportional
hazards (Cox) regression analyses were applied to test the
SUVmax’s independency of other prognostic factors for the
prediction of overall survival.
Results The median duration of follow-up was 981 days
(2.7 years). The median SUVmax was 5.9 for all subjects, 4.5
for stage IA, 8.4 for stage IB, and 10.9 for stage IIB. The
optimal cutoff SUVmax was 8.2 for all subjects. No optimal
cutoff could be established for specific stages. In univariate
analyses, each doubling of SUVmax [i.e., each log (base 2)
unit increase in SUVmax] was associated with a 1.28-fold
[95% confidence interval (CI): 1.03–1.59, p=0.029]increase
in hazard of death. Univariate analyses did not show any
significant difference in survival by SUVmax when data were
stratified according to pathological stage (p=0.119, p=0.818,
and p=0.882 for stages IA, IB, and IIB, respectively).
Multivariate analyses demonstrated that SUVmax was not an
independent predictor of overall survival (p>0.05).
Conclusion Each doubling of SUVmax as determined by
preoperative PET is associated with a 1.28-fold increase in
hazard of death in early-stage (I & II) NSCLC. Preoperative
SUVmax is not an independent predictor of overall survival.
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Introduction
18F-Fluoro-2-deoxyglucose (
18F-FDG) positron emission
tomography (PET) has been demonstrated to be very useful
in the diagnosis and staging of non-small cell lung cancers
(NSCLC) [1, 2]. As a result there has been increasing
interest in the prognostic utility of the preoperative
standardized uptake value (SUV) of the primary tumor.
Many prior studies have investigated this issue [3–16].
Several prior studies have reported an association between
higher maximum SUV (SUVmax) and poor prognosis, but
some recent studies have failed to find any independent
correlation between them. To elucidate the prognostic
significance of preoperative SUVmax of the primary tumor
in early-stage (I & II) NSCLC, a retrospective review of
363 consecutive patients who had a preoperative
18F-FDG
PET done before undergoing attempted curative resection
for early-stage (I & II) NSCLC was performed.
Materials and methods
Approval of human data exemption was obtained from the
Institutional Review Board for this Health Insurance Porta-
bility and Accountability Act (HIPAA) compliant study.
Objectives
The aims were to determine if SUVmax as measured by
preoperative
18F-FDG PET is an independent predictor of
survival and to determine if SUVmax as measured by
preoperative
18F-FDG PET is of prognostic value after
stratification according to pTNM staging.
Study population
Subjects were identified through the institutional tumor
registry.
Patients were included in the study if they had a
preoperative
18F-FDG PET done from 5 February 1999
through 21 March 2007 before undergoing attempted
curative resection for pathologically documented stage I
and II NSCLC and histological diagnosis was available.
Patients were excluded from the study if they had received
any adjuvant or neoadjuvant chemotherapy or radiation
therapy, had any prior history of lung cancer, or if SUVmax
was not available due to the non-availability of SUVmax from
the reports and the non-availability of PET images.
PET
Scans performed since July 2004 were obtained by a
dedicated 16-slice whole-body PET/CTscanner (GE Discov-
ery DST, GE Medical Systems, Milwaukee, WI, USA). All
patients with 4-h fasting before the examination received an
average of 560 MBq
18F-FDG intravenous injections. PET
images were obtained 1 h after injection. The PET images
were obtained at each bed position for 3 min with six to eight
bed positions to cover the entire body. The PET images were
obtained using a two-dimensional high-sensitivity mode with
an axial field of view of 15 cm in a 256×256 matrix. A 3-
slice overlap was utilized between the bed positions. The
PET images were reconstructed iteratively on a 128×128
matrix using an ordered subsets expectation maximization
algorithm for 30 subsets and two iterations, with a 7.0-mm
post-reconstruction filter. In-plane resolution of 6.2 mm and
axial resolution of 5.0 mm was obtained. Concomitant CT
data were used for attenuation correction of all PET images
in the quantitative analysis of SUV. The CT component of
image acquisition used the following imaging parameters:
140 kVp, 120–200 mA, 0.8 s per CT rotation, pitch 1.75:1,
detector configuration of 16×1.25 mm, and 3-mm slice
thickness with oral contrast only.
PET and CT images were merged (fusion analysis) for
functional and anatomic correlation. CT/PET images were
displayedonAW/XelerisandMedviewworkstations(General
Electric Medical Systems, Milwaukee, WI, USA and Medi-
mage, Ann Arbor, MI, USA). Scans performed before July
2004 were obtained on a dedicated whole-body PET only
scanner (Advance, General Electric Medical Systems, Mil-
waukee, WI, USA) 1 h after injection of
18F-FDG (370 MBq,
on average) and after the patients had fasted about 4 h. PET
images were reconstructed using an iterative reconstruction
algorithm with segmented attenuation correction. All PET
data were visually examined and compared to the patient’s
recent CT. The decision was finally made by correlating PET
with CT to make sure the non-tumor regions were excluded
from analysis. The SUV from both cameras were validated
and correlated with phantom studies.
SUV was calculated using the following formula:
SUV ¼ lung cancer activity= dose=body mass ðÞ
The SUVmax was obtained by selecting volumetric regions
of interest (VOIs) within the primary cancer site to include
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potentially higher SUV than that of the tumor. The glucose
concentration was also recorded for each patient before the
injection of the
18F-FDG radiotracer in each PET scan.
Data collection
In 325 subjects SUVmax of the primary tumor was obtained
from the initial PET reports. PET study interpretation had
been independently performed by five experienced nuclear
medicine physicians. In 38 subjects SUVmax was calculated
from the PET images as it was not reported in the initial
PET reports.
Baseline demographic, clinical, and tumor character-
istics, treatment, follow-up, and survival data were obtained
from the electronic medical record system and institutional
tumor registry records.
The histological type was categorized according to the
WHO classification system [17].
End-point assessment
The primary outcome measure was the duration of overall
survival. It was measured from the date of surgery to the
date of death from any cause with surviving patients
censored at the time of last contact.
Statistical methods
Variables studied included age, race, gender, preoperative
SUVmax, pathological stage, tumor size, tumor laterality,
type of surgery, histology subtype, and cytologic grade.
The continuous variables SUVmax, tumor size, and age
were examined for normality and skewness. SUV and
tumor size needed log transformations (with base 2).
Each variable was analyzed using univariate proportional
hazards (Cox) regression analysis. Multivariate proportional
hazards (Cox) regression analyses were applied to test the
SUVmax’s independency of other prognostic factors for the
prediction of overall survival.
In the initial multivariate Cox regression model, all
variables that on univariate analysis were found to have a
p value of less than 0.10 were included as covariates.
SUVmax, tumor size, and age were treated as continuous
variables. Variables were retained in the subsequent Cox
regression modeling if they met the p value of less than
0.05 in the model. Nonsignificant variables were removed
by stepwise backward elimination. Pathological staging
was excluded from multivariate analysis due to potential
interaction with tumor size.
The continuous variables SUVmax, tumor size, and age
were then dichotomized by a median split. Survival curves
stratified by median SUVmax were estimated by the Kaplan-
Meier method and statistical differences were assessed
using the log-rank test. Multivariate analyses were repeated
after replacing continuous variables with median SUVmax,
median tumor size, and median age.
Receiver-operating characteristic (ROC) curves were plot-
ted to find out the optimal cutoff values of SUVmax yielding
the maximal sensitivity plus specificity for predicting the
overall survival. Survival curves stratified by optimal cutoff
SUVmax were estimated by the Kaplan-Meier method, and
statistical differences were assessed using the log-rank test.
Multivariate analyses were performed again after replacing
median SUVmax with optimal cutoff SUVmax.
The data were then stratified according to the patholog-
ical stage. The median SUVmax for each specific stage was
calculated. For specific stages, survival curves stratified by
median SUVmax were estimated by the Kaplan-Meier
method, and statistical differences were assessed using the
log-rank test. By plotting the ROC curves, we attempted to
find out the optimal cutoff values of SUVmax for specific
stages yielding the maximal sensitivity plus specificity for
predicting the overall survival, but none could be estab-
lished. No stage-specific analysis was performed for stage
IIA due to the small number of subjects.
Statistical analyses were performed using SPSS® version
13.0 (SPSS Inc., Chicago, IL, USA).
In order to address the effects of the partial volume
effects, the recovery coefficient (RC) was determined, and
the SUVmax was corrected using the diameters of the tumor
as the following:
SUVmeasured ¼
Counts:CF kBq=ml=kg ðÞ
ID kBq=ml ðÞ =Mass kg ðÞ
where CF = calibration factor and ID = injected dose.
The partial volume correctedSUV (SUVpvc) was given by:
SUVpvc ¼ SUVbkg þ SUVmeasured   SUVbkg
 
RC
where SUVbkg = background SUV.
Results
A total of 363 subjects met the inclusion and exclusion
criteria. The median duration between preoperative
18F-FDG
PET and attempted curative resection was 38 days. The
median duration of follow-up was 981 days (2.7 years). The
clinicopathologic characteristics are summarized in Table 1
along with the mortality information.
The median SUVmax was 5.9 for all subjects, 4.5 for
stage IA, 8.4 for stage IB, and 10.9 for stage IIB (Fig. 1).
The optimal cutoff value of SUVmax was 8.2 for all
subjects. No optimal cutoff value of SUVmax could be
established for specific stages with acceptable sensitivity
and specificity for predicting the overall survival. No stage-
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small number of subjects.
In univariate proportional hazards (Cox) regression
analysis, each doubling of SUVmax [i.e., each log (base 2)
unit increase in SUVmax] was associated with a 1.28-fold
[95% confidence interval (CI): 1.0–1.6, p=0.029] increase
in hazard of death (Table 2). Kaplan-Meier survival
analyses showed significant difference in overall survival
when stratified by median SUVmax (Fig. 2) and optimal
cutoff SUVmax (Fig. 3) in the whole group of cases (log-
rank test, p=0.018 and p=0.004, respectively). The mean
survival times of patients with SUVmax of primary tumor
equal to or more than median value 5.9 and optimal cutoff
value of 8.2 were 66.6 months and 58.9 months, respec-
tively, compared with overall mean survival time of
73.5 months.
Primary analysis with the multivariate Cox proportional
hazards model showed that SUVmax was not an indepen-
dent predictor of overall survival (p>0.05). Repeat analyses
after replacing the continuous variables tumor size, age, and
SUVmax with the dichotomous variables median tumor size,
median age, and median SUVmax or optimal cutoff SUVmax
again failed to show the SUVmax’s independency of other
prognostic factors for the prediction of overall survival (p>
0.05 in all multivariate models).
There was high correlation between SUVpvc and the
uncorrected SUVmax (Fig. 4). Thus, the statistical analysis
on the original data is still valid.
Table 1 Patient characteristics
Variable Total (n) Died (n) Died (%) Censored (n)
Pathological TNM stage
Stage IA 223 34 15.20 189
Stage IB 112 25 22.30 87
Stage IIA 8 1 12.50 7
Stage IIB 20 6 30.00 14
Laterality
Right 224 40 17.90 184
Left 139 26 18.70 113
Type of surgery
Lobectomy 293 53 18.10 240
More extensive resection (bilobectomy or pneumonectomy) 18 6 33.30 12
Limited resection (wedge/segment/lingular resection) 52 7 13.50 45
Tumor grade
Low grade 73 11 15.10 62
Intermediate grade 153 28 18.30 125
High grade 131 27 20.60 104
Histology type
Squamous cell carcinoma 90 19 21.10 71
Adenocarcinoma 227 41 18.10 186
Others 46 6 13.00 40
Age group
<50 years 17 0 0.00 17
50–59 years 49 3 6.10 46
60–69 years 112 16 14.30 96
70–79 years 139 38 27.30 101
>79 years 46 9 19.60 37
Race
White 344 63 18.30 281
Others 19 3 15.80 16
Sex
Male 175 39 22.30 136
Female 188 27 14.40 161
Overall 363 66 18.20 297
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The resolution reported in the method section was at 1 cm.
In a realistic clinical setting, the resolution at 10 cm will be
a better representation. The full-width half-maximum
(FWHM) tangential resolution of PET alone camera was
4.9 mm and the radial resolution was 4.4 mm compared to
that of respective resolutions of PET/CT at 5.8 and 6.6 mm.
Thus, our average tumor size exceeded twice that of
FWHM in both PET cameras.
Subgroup analyses
Univariate proportional hazards (Cox) regression analyses
did not show any significant difference in survival by
SUVmax when data were stratified according to the
pathological stage (p=0.119, p=0.818, and p=0.882 for
pTNM stages IA, IB, and IIB, respectively, Table 2).
Kaplan-Meier survival analyses also did not detect any
significant survival differences in any of the pathological
stage subgroups considered when patients were stratified
according to the stage-specific median SUVmax (log-rank
test, p=0.071, p=0.682, and p=0.928 for pTNM stages IA,
IB, and IIB, respectively, Figs. 5, 6, and 7).
Discussion
Several studies in the past have reported that preoperative
SUV is of prognostic value in early-stage (I & II) NSCLC
[3–11, 14, 15]. But some recently published data have cast
Fig. 1 Frequency distribution
of SUVmax
Univariate proportional hazards (Cox) regression analyses
Hazard ratio (per factor of 2 increase in SUVmax) 95.0% CI for HR p
Stage IA 1.296 0.935–1.796 0.119
Stage IB 1.047 0.709–1.546 0.818
Stage IIB 1.054 0.528–2.105 0.882
All stages 1.276 1.025–1.590 0.029
Table 2 Univariate proportional
hazards (Cox) regression analy-
ses
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reported similarly disappointing results in advanced-stage (III
& IV) NSCLC. The results of the current study are consistent
with these recent studies. They confirmed the observation that
in early-stage (I & II) NSCLC patients with higher SUV had
significantly higher risks of dying; but they also demonstrated
that preoperative SUV was not an independent predictor of
survival. Some studies have dichotomized age [9, 14]. This
can result in significant loss of statistical power [18], which
may cause underestimation of the prognostic importance of
age and thus can lead to overestimation of the prognostic
importance of other variables in the multivariate models.
Other studies did not include age in the multivariate models
[3, 4]. Tumor size was also not included in the multivariate
models in many prior studies [9, 14], which has been an
important prognostic factor. In addition, many of them did
not control for other potential confounding factors or were
limited by small sample size [5–7, 9, 15]. Some studies did
not report multivariate analysis results [5, 11, 15]. It is
believed that all these factors can at least partly explain the
different conclusions reached.
Several studies have tried to establish optimal SUV cutoff
values that differentiate between good and poor prognosis
groups in NSCLC. Numerous cutoffs have been suggested.
These cutoffs have ranged from 4.3 to 10 [3, 4, 6, 7, 9, 10,
12, 13]. But this approach has the risk of artificial reduction
in p values and overestimation of prognostic significance
[19]. These cutoff points may be data specific and can also
introduce a statistical artifact known as the Will Rogers
phenomenon [20]. This has made comparison between
different studies difficult. Prior studies have tried dichotomi-
Fig. 5 Kaplan-Meier survival curves by median SUVmax (4.5) in
stage IA patients (log-rank p=0.071)
Fig. 4 Effects of partial volume
Fig. 3 Kaplan-Meier survival curves by optimal cutoff SUVmax (8.2)
in all subjects (log-rank p=0.004)
Fig. 2 Kaplan-Meier survival curves by median SUVmax (5.9) in all
subjects (log-rank p=0.018)
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significant loss of statistical power and therefore might not
be suitable for estimation of prognosis [18]. A few authors
have tried grouping subjects into more than two groups [5,
11]. The present study analyzed SUVmax as a continuous
variable in early-stage (I & II) NSCLC. This prevented the
introduction of all the biases associated with dichotomization
and results in maximal statistical power. Another strength of
the current study was the exclusion of patients who had
received any adjuvant or neoadjuvant chemotherapy or
radiation therapy. This avoided the profound confounding
effect of multiple treatment protocols. Also the current study
population was one of the largest reported to date allowing
statistical analyses for adjustment for potential confounders.
Moreover, to facilitate comparison with prior studies,
additional analyses after dichotomization of SUVmax at both
optimal cutoff value and median SUVmax were performed.
All three methods produced similar results. Therefore, we
believe that our results are valid and generalizable. Although
no sharp natural binary cutoff likely exists, the higher the
preoperative SUVmax, the higher the probability of death.
Subgroup analyses
Recently Hannin et al. [15] reported that in stage I high
SUVmax was associated with significantly decreased overall
survival. In this study stage I was not subclassified into stages
IA and IB. The current study demonstrated that SUVmax
would lose its prognostic value after stratification according
to pathological staging into IA, IB, and IIB. The current
results are consistent with those reported by Downey et al.
[13]. In their study prediction of survival by SUVmax was not
found to be independent of pathological staging in early-stage
NSCLC. In fact, in our study when pTNM stage subgroups
IA and IB were combined, univariate proportional hazards
(Cox) regression analysis and Kaplan-Meier survival analysis
did detect significant survival differences. Thus, the findings
of Hannin et al. may be due to the combining of stages IA
and IB cancers. Cerfolio et al. [10] also reported a very
significant (p<0.001) difference in overall survival when all
patients were stratified by a SUVmax of 10. But this p value
rose dramatically in stage-specific analysis when patients
were stratified by stage-specific median SUVmax values (p not
significant, p=0.048, and p=0.028 for stages IA, IB, and II,
respectively; no separate p values for stages IIA and IIB were
reported). Many previous studies have used the median or
optimal cutoff SUV of the combined sample for the stage-
specific analysis [6, 13]. As higher stage NSCLC tumors
have higher SUV [10], pathological stage distribution of the
study population significantly affects the calculated median
and optimal cutoff SUV of the combined sample. This has
made comparison between different studies difficult. Also
one SUV cutoff might not be suitable for all stages. This
issue was addressed by using stage-specific median SUVmax
for stage-specific analysis. This yielded more generalizable
results. The study also showed that there was no stage-
specific optimal cutoff value for pTNM stages IA, IB, or IIB
with acceptable sensitivity and specificity for predicting the
overall survival. This strengthens the conclusion that SUVmax
loses its prognostic value after stratification according to
pathological staging.
Limitations
One limitation of the study was the retrospective nature of
the data. Also the relatively small number of stage II
Fig. 7 Kaplan-Meier survival curves by median SUVmax (10.85) in
stage IIB patients (log-rank p=0.928)
Fig. 6 Kaplan-Meier survival curves by median SUVmax (8.4) in
stage IB patients (log-rank p=0.682)
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possible. This has been a recurrent problem for studies which
assessed the outcome of surgically treated early lung cancer
patients[6, 9, 13]. Despite these limitations, the current study
provides important insights into the prognostic importance of
preoperative SUVmax. However, the results were comple-
mentary to a previous publication, which was one of the first
investigations to declare the absence of relation between
SUVand prognosis in 178 patients [21]. Until more data are
available to determine this conclusively, it is prudent to avoid
making any treatment decisions solely on the basis of
preoperative SUVmax without considering other tumor and
patient characteristics. Ultimately, a prospective study with
even a larger sample size than the current study is needed to
conduct stage-specific analyses.
Conclusion
The results demonstrate that each doubling of SUVmax as
determined by preoperative PET is associated with a 1.28-
fold increase in hazard of death in early-stage (I & II)
NSCLC. Preoperative SUVmax is not an independent
predictor of overall survival in that it loses its prognostic
value in multivariate analyses and also after stratification
according to pathological staging.
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